Riamilovir is a broad-spectrum antiviral agent belonging to the triazole-triazine class, primarily utilized for the treatment of influenza A and B viruses, including strains such as H5N1. This category… Read more
Riamilovir is a broad-spectrum antiviral agent belonging to the triazole-triazine class, primarily utilized for the treatment of influenza A and B viruses, including strains such as H5N1. This category features high-quality reference standards for the Riamilovir active pharmaceutical ingredient (API), alongside related compounds such as pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled derivatives. These materials serve as essential tools for analytical testing, impurity profiling, and method validation within pharmaceutical research and quality control laboratories. By providing accurate benchmarks for identification and quantification, these standards assist scientists in ensuring the rigorous safety and efficacy testing of antiviral formulations. Whether utilized for method development or regulatory compliance, these critical reference materials support the precise analysis required to maintain standards in drug manufacturing and development.